"Chasing the Miracles of Science to Improve Lives"
1. Company Snapshot
🌍 Headquarters: Paris, France
🌐 Global Presence: 100+ countries | 91,000 employees
📅 Founded: 1973 (merged with Synthélabo in 1999)
🏦 Public: Euronext: SAN | 💰 Market Cap: €120B
🔬 R&D Hubs: France, US, Germany, China
💻 Careers: Sanofi Careers
2. Mission, Vision & Values
🧬 Mission:
“To transform scientific innovation into healthcare solutions”
👁️ Vision:
“To be the first biopharma company powered by AI at scale”
🌟 Core Values:
- Patient-Centricity
- Courage
- Integrity
Culture: 4.0/5 Glassdoor | “Science-driven with strong French heritage”
3. Key Leadership
| Role | Name | Leadership Style |
|---|---|---|
| CEO | Paul Hudson | Digital Transformer |
| CSO | Dietmar Berger | Immunology Expert |
4. Key Milestones
2011: Acquired Genzyme ($20B)
2019: Dupixent approved (now €10B+ drug)
2022: Pivoted to “Play to Win” strategy
2023:
- Acquired Provention Bio ($2.9B)
- Launched AI-powered R&D platform
5. Business Model & Position
💰 Revenue Streams:
- 40% Specialty Care (Dupixent, etc.)
- 30% Vaccines
- 20% General Medicines
- 10% Consumer Healthcare
🆚 Key Competitors:
| Company | Differentiator |
|---|---|
| Novartis | Stronger oncology pipeline |
| GSK | Vaccine leadership |
6. Industry Trends & Challenges
📈 Opportunities:
- Immunology leadership (Dupixent)
- AI-driven drug discovery
- mRNA vaccine expansion
⚠️ Challenges:
- Lantus biosimilar competition
- Diabetes franchise decline
7. Financial Health (2023)
| Metric | Value | Industry Rank |
|---|---|---|
| Revenue | €43B | #5 Pharma |
| R&D Investment | €6.7B | Top 10 in R&D |
| Operating Margin | 24.5% | Above Average |
8. SWOT Analysis
💪 Strengths:
- #1 in immunology (Dupixent)
- Strong vaccine infrastructure
📉 Weaknesses:
- Overdependence on Dupixent
- Weak oncology pipeline
🌱 Opportunities:
- Type 1 diabetes prevention
- Rare disease expansion
⚠️ Threats:
- US drug pricing reforms
- mRNA vaccine competition
9. Recent Developments
🔬 Innovations:
- FDA approval for Tzield (diabetes delay)
- 12 new molecular entities in Phase III
🤝 Partnerships:
- OpenAI AI collaboration
- mRNA partnership with Translate Bio
10. Interview Toolkit
Must-Know:
- “Play to Win” strategy pillars
- Dupixent’s market dominance
Smart Questions:
“How is Sanofi balancing small molecules vs biologics in R&D?”
11. Conclusion
Sanofi transforms healthcare through:
🔹 Immunology breakthroughs
🔹 Vaccine legacy + mRNA future
🔹 AI-powered R&D transformation